1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. 2004 The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 44(4):398-404.
2. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008 Nov;52(5):818-27.
3. David A. Calhoun, Chair; Daniel Jones, Stephen Textor, David C. Goff, Timothy P. Murphy, Robert D. Toto, Anthony White,  William C. Cushman, William White, Domenic Sica, Keith Ferdinand, Thomas D. Giles, Bonita Falkner, Robert M. Carey, Resistant Hypertension: Diagnosis, Evaluation,and Treatment
A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.Hypertension 2008, 51:1403-1419.
4. Aram V. Chobanian et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289:2560.
5. Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011 Mar;43(3):153-64.
6. Ullah MI, Uwaifo GI, Nicholas WC, Koch CA. Does vitamin D deficiency cause hypertension ? Current evidence from clinical studies and potential mechanisms. Int J Endocrinol. 2010;2010:579640.
7. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary andsecondary hypertension: studies in a random population sample. Br MedJ1976;2(6035):554–556.
8. Working Group on Renovascular Hypertension. Detection, evaluation,and treatment of renovascular hypertension. Final report. Arch Intern Med1987;147(5):820–829.
9. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens1994;12(5):609–615.
10. Bech K, Hilden T. The frequency of secondary hypertension. Acta Med Scand1975;197(1–2):65–59.
11.Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344(6):431–442.
12. Senitko M, Fenves AZ. An update on renovascular hypertension. Curr Cardiol Rep2005;7(6):405–411.
13. Krumme B, Donauer J. Atherosclerotic renal artery stenosis and reconstruction.Kidney Int 2006;70(9):1543–1547.
14.The pathogenesis of acute pulmonary edema associated with hypertension.AU Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, Little WC SO N Engl J Med. 2001;344(1):17.
15.ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease, American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for Vascular Nursing, TransAtlantic Inter-Society Consensus, Vascular Disease Foundation.Circulation. 2006;113(11):e463.
16. Boudewijn B, Vasbinder C, Nelemans PJ, Kessels GH, Kroon AA, de Leeuw PW, van Engleshoven JMA. Diagnostic test for renal artery stenosis in patients suspected of having renovascular hypertension: A meta-analysis. Ann Intern Med 2001; 135:401-411.
17.Goldman CK, Chi YW. Magnetic resonance, computed tomographic, and angiographic imaging of peripheral arterial disease. In: Mohler E, Jaff M, eds. Peripheral Arterial Disease.1st edition. American College of Physicians. 2008;53-72.
18. A Prospective Study of Carbon Dioxide—Digital Subtraction vs Standard Contrast Arteriography in the Evaluation of the Renal Arteries David Z. Schreier, MD; Fred A. Weaver, MD; Joseph Frankhouse, MD; George Papanicolaou, MD; Ernest Shore, MD; Albert E. Yellin, MD; Frances Harvey, RN.Arch Surg. 1996;131(5):503-508.
19. Olusegun O. Osinbowale, Yung-Wei Chi, Imaging for Renal Artery Stenosis and In-Stent Restenosis, Duplex ultrasound, CTA, and MRA for the imaging diagnosis of renal artery disease. Endovascular Today, November 2008, pp. 32-41.
20. Dong Q, Schoenberg SO, Carlos RC, et al. Diagnosis of renal vascular disease with MR angiography. Radiographics 1999;19:1535-1554.
21. Richmond H, Zwerner J, Kim Y, et al. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol. 2007;143:1025-1030. Erratum in: Arch Dermatol. 2007;143:1565.
22. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens. 2008;17:315-319.
23. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-806.
24. Olin JW, Piedmonte MR, Young JR, et al. The utility of duplex ultrasound scanning of the
renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med. 1995;122:833-838.
25. Setaro JF, Chen CC, Hoffer PB, Black HR. Captopril renography in the diagnosis of renal artery stenosis and the prediction of improvement with revascularization. The Yale Vascular Center experience. Am J Hypertens1991;4(12 Pt 2):698S-705S.
26. Bongers V, Bakker J, Beutler JJ, Beek FJ, De Klerk JM. Assessment of renal artery stenosis: comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. Clin Radiol 2000; 55(5):346-353.
27. Mann SJ, Pickering TG. Detection of renovascular hypertension. State of the art: 1992. Ann Intern Med. 1992;117: 845-853.
28. Pedersen EB. Angiotensin-converting enzyme inhibitor renography. Pathophysiological, diagnostic and therapeutic aspects in renal artery stenosis. Nephrol Dial Transplant 1994;9: 482-492.
29. Modified after: J.E.Hall, L. K. Nieman, Handbook of diagnostic endocrinology, Cushing’s  Syndrome, pg. 67-83, 2003.
30. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B 1997 Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem 1997;34(Pt3):222-229.
31. Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB Jr .A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993;77(5):1308.
32. Sheldon WR Jr, DeBold CR, Evans WS, DeCherney GS, Jackson RV, Island DP, Thorner MO, Orth DN. Rapid sequential intravenous administration of four hypothalamic releasing hormones as a combined anterior pituitary function test in normal subjects. J Clin Endocrinol Metab 1985;60(4):623.
33. Findling JW, Kehoe ME, Shaker JL, Raff H. Routine inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing's syndrome: early recognition of the occult ectopic ACTH syndrome. J Clin Endocrinol Metab 1991;73:408-413.
34. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB, Jr, Loriaux DL Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991;325:897-905.
35. Kaltsas GA, Giannulis MG, Newell-Price JD, Dacie JE, Thakkar C, Afshar F, Monson JP, Grossman AB, Besser GM, Trainer PJ. A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999;84:487-492.
36. Landolt AM, Schubiger O, Maurer R, Girard J. The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease. Clin Endocrinol (Oxf) 1994;40:485-492.
37. Invitti C, Giraldi FP, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999;84:440-448.
38. Doppman JL, Frank JA, Dwyer AJ, Oldfield EH, Miller DL, Nieman LK, Chrousos GP, Cutler GB, Jr., Loriaux DL.Gadolinium DTPA enhanced MR imaging of ACTH-secreting microadenomas of the pituitary gland. J Comput Assist Tomogr 1988;12:728-735.
39. Patronas N, Bulakbasi N, Stratakis CA, Lafferty A, Oldfield EH, Doppman J, Nieman LK. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 2003;88:1565-1569.
40. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 1994; 120:817-820.
41. Escourolle H, Abecassis JP, Bertagna X, Guilhaume B, Pariente D, Derome P, Bonnin A, Luton JP. Comparison of computerized tomography and magnetic resonance imaging for the examination of the pituitary gland in patients with Cushing's disease. Clin Endocrinol (Oxf) 1993;39:307-313.
42. de Herder WW, Lamberts SW Tumor localization--the ectopic ACTH syndrome. J Clin Endocrinol Metab 1999;84:1184-1185.
43. Tabarin A, Valli N, Chanson P, Bachelot Y, Rohmer V, Bex-Bachellerie V, Catargi B, Roger P, Laurent F.Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1999;84:1193-1202.
44. Torpy DJ, Chen CC, Mullen N, Doppman JL, Carrasquillo JA, Chrousos GP, Nieman LK 1999 Lack of utility of (111)In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: follow-up of 18 patients. J Clin Endocrinol Metab 84:1186-1192.
45. Singer J, Werner F, Koch CA, Bartels M, Aigner T, Lincke T, Fasshauer M, Paschke R. Ectopic Cushing’s syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010 Aug;118(8):524-529.
46. Kumar J, Spring M, Carroll PV, Barrington SF, Powrie JK 2006 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin Endocrinol (Oxf) 64:371-374 .
47. Haoping Xu, Min Zhang,Ge Zhai,Miao Zhang,Guang Ning,Biao Li, The role of integrated 18F-FDG PET/CT in identification of ectopic ACTH secretion tumors. Endocr (2009) 36:385–391 DOI 10.1007/s12020-009-9247-2.
48. A. Markou, P. Manning, B. Kaya, S.N. Datta, J.B. Bomanji, G.S. Conway, [18F] Fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing’s syndrome. Eur. J. Endocrinol. 152, 521–525 (2005).
49. J. Kumar, M. Spring, P.V. Carroll, S.F. Barrington, J.K. Powrie, 18Flurodeoxyglucose positron emission tomography in the localization of ectopic ACTH-secreting neuroendocrine tumours. Clin. Endocrinol. 64, 371–374 (2006).
50. A.B. Moraes, G.F. Taboada, M.P. Carneiro, L.V. Neto, L.E. Wildemberg, K. Madi et al., Utility of [18F] fluoro-2-deoxy-Dglucose positron emission tomography in the localization of ectopic ACTH-secreting tumors. Pituitary 2009.
51. Modified from:Marco Boscaro,Giorgio Arnaldi. Approach to the Patient with Possible Cushing’s Syndrome. J Clin Endocrinol Metab, September 2009, 94(9):3121–3131
52. Jackson RV, Lafferty A, Torpy DJ, et al. New genetic insights in familial hyperaldosteronism.
Ann N Y Acad Sci 2002;970:77–88.
53. O’Mahony S, Burns A, Murnaghan DJ. Dexamethasone-suppressible hyperaldosteronism: a large new kindred. J Hum Hypertens 1989;3(4):255–8.
54. Litchfield WR, Anderson BF, Weiss RJ, et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31(1 Pt 2):445–50.
55. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008;93(9):3266–81.
56. Dluhy RG, Anderson B, Harlin B, et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 2001;138(5):715–20.
57. Stowasser M, Bachmann AW, Huggard PR, et al. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab 2000;85(6):2160–6.
58. Rich GM, Ulick S, Cook S, et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992;116(10):813–20.
59. Ganguly A, Crim CE, Weinberger MH. Anomalous postural aldosterone response in glucocorticoid-suppressible hyper-aldosteronism. New Engl J Med 1981;305:991-993.
60. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem & Mole Biol. 2001;78:215-229.
61. Ulick S, Chu MD. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension. Clin Exp Hypertens 1982;A4:1771-1777.
62. Ulick S, Chu MD, Land M. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue. J Biol Chem 1983;258:5498-5502.
63. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediabel aldosteronism. J Clin Endocrine and Metabolism 1997;82:3570-3572.
64. Connell JMC, Kenyon CJ, Corrie JET, Fraser R, Watt R, Lever AF. Dexamethasone-suppressible hyperaldosteronism: adrenal transitional cell hyperplasia? Hypertension 1986; 8:669-676.
65. New MI, Peterson RE, Saenger P, Levine LS. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. J Clin Endocrinol Metab 1976; 43:1283-1293.
66. Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties. J Hypertens 2000; 18:1165-1176.
67. Fardella CE. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001;86(10):4805–7.
68. Jamieson A, Inglis GC, Campbell M, Fraser R, Connell JMC. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents. Arch Dis Child 1994; 71:40-43.
69. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262-265.
70. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82:3570-3573.
71. Stowasser M, Gartside MG, Gordon RD. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for Familial Hyperaldosteronism Type 1. Aust NZ J Med 1997; 27:685-690.
72. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045–1050.
73. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J 2000 Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85:1863–1867.
74. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE 2003 Primary aldosteronism and hypertensive disease.Hypertension 42:161–165.
75. Schwartz GL, Turner ST 2005 Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51:386–394.
76. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F 2002 High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives.AmJ Hypertens 15:896–902.
77. Strauch B, Zelinka T,Hampf M,Bernhardt R, Widimsky Jr J 2003 Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 17:349–352.
78. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR 2006 Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 20:129–136.
79. Benchetrit S, Bernheim J, Podjarny E 2002 Normokalemic hyperaldosteronism in patients with resistant hypertension. Isr Med Assoc J 4:17–20.
80. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P 2002 Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40:892–896.
81. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP 2004 Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens22:2217–2226.
82. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC 2001 Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37:699–705
83. Goodfriend TL, Calhoun DA 2004 Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43:518–524.
84. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM 2004 Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125:112–117.
85. Aso Y,HommaY 1992 A survey on incidental adrenal tumors in Japan. J Urol 147:1478–1481.
86. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M 2003 Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273–285.
87. Bulow B, Ahren B 2002 Adrenal incidentaloma: experience of a standardized diagnostic program in the Swedish prospective study. J Intern Med 252:239–246.
88. Caplan RH, Strutt PJ, Wickus GG 1994 Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg 129:291–296.
89. Kim HY, Kim SG, Lee KW, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS 2005 Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 20:303–309.
90. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.J Clin Endocrinol Metab 85:637–644.
91. John W. Funder, Robert M. Carey, Carlos Fardella, Celso E. Gomez-Sanchez, Franco Mantero, Michael Stowasser, William F. Young Jr., and Victor M. Montori. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. September 2008, 93(9):3266–3281.
92. McKenna TJ, Sequeira SJ, Heffernan A, et al. Diagnosis under random conditions of all disorders of rennin–angiotensin–aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991;73:952–7.
93. Gordon RD, Tunny TJ. Aldosterone-producing adenoma (A-P-A): effect of pregnancy. Clin Exp Hypertens A 1982;4:1685–93.
94. Murphy BF, Whitworth JA, Kincaid-Smith P. Malignant hypertension due to an aldosterone producing adrenal adenoma. Clin Exp Hypertens A 1985;7:939–50.
95. Buhler FR, Laragh JH, Baer L, et al. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972;287:1209–14.
96. Gordon MS, Williams GH, Hollenberg NK. Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade. Endocr Res 1992;18:115–31.
97. Mulatero P, Rabbia F, Milan A, et al. Drug effects on aldosterone/plasma rennin activity ratio in primary aldosteronism. Hypertension 2002;40:897–902.
98. Oparil S. Review of therapeutic modalities acting directly via central pathways. Clin Exp Hypertens A 1982;4:579–93.
99. Manhem P, Ho¨kfelt B. Prolonged clonidine treatment: catecholamines, renin activity and aldosterone following exercise in hypertensives. Acta Med Scand 1981;209:253–60.
100. Gordon RD. Diagnostic investigations in primary aldosteronism. In: Zanchetti A, ed. Clinical medicine series on hypertension. Maidenhead: McGraw-Hill, 2001:101–14.
101. Cappuccio FP, Markandu ND, Sagnella GA, et al. Effects of amlodipine on urinary sodium excretion, rennin–angiotensin–aldosterone system, atrial natiuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991;5:115–19.
102. Fiad TM, Cunningham SK, Hayes FJ, et al. Effects of nifedipine treatment on rennin– angiotensin–aldosterone axis. J Clin Endocrinol Metab 1997;82:457–60.
103. Brown MJ, Hopper RV. Calcium-channel blockade can mask the diagnosis of Conn’s syndrome. Postgrad Med J 1999;75:235–6.
104. Lamarre-Cliche´ M, de Champlain J, Lacourciere Y, et al. Effects of circadian rhythms, posture, and medication on rennin–aldosterone interrelations in essentialhypertensives. Am J Hypertens 2005;18:56–64.
105. Lyons DF, Kem DC, Brown RD, et al. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983;57:892–6.
106. Guthrie GP Jr, McAllister RG Jr, Kotchen TA. Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man. J Clin Endocrinol Metab 1983;57:339–43.
107. Leenen FH, Smith DL, Farkas RM, et al. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med 1987;82:969–78.
108. Weinberg MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med. 1993; 153:2125-2129.
109. Young WF. Primary aldosteronism: management issues. NY Acad Sci 2002; 970:61-76.
110. Ross E, Regolisti G, Negro A, Sani C, Davoli S, Preazoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15:896-9025.
111. Racine MC, Douville P, Lebel M. Functional tests for primary aldosteronism: value of captopril suppression. Curr Hypertens Rep. 2002; 4:245-249.
112. Castro Ol, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary aldosteronism. Hypertension 2002;39:935-938.
113. Bravo EL, Tarazi RC, Dustan HP, et al. The changing clinical spectrum of primary aldosteronism.  Am J Med 1993; 74:641-651.
114. Young WF Jr. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997; 7:213-221.
115. Ganguly A. Primary Aldosteronism. New England Journal of Medicine 1998; 1828-1834.
116. Agharazii M, Douville P, Grose JH, Lebel M 2001 Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37:1440–1443.
117. Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C 1981 Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci (Lond) 61 (Suppl 7):289s–293s.
118. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F 2007 Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 50:424–431.
119. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallin M, Feltrin GP, Pessina AC. Identification of the etiology of primary aldosteronism with adrenal vein sampling in  patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab  2001: 86: 1083-90.
120. Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in primary bilateral aldosteronism: a 22-year single center experience. J Clin Endocrinol Metab 2009;94:2437-2445.
121. Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 2011;96:2904-2911.
122. Suzuki K, Fujita K, Ushiyama T, Mugiya S, Kageyama S & Ishikawa A. Efficacy of an ultrasonic surgical system for laparoscopic adrenalectomy. Journal of Urology 1995 154 484–486.
123. Abrams HL, Siegelman SS, Adams DF, Sanders R, Finberg HJ, Hessel SJ & McNeil BJ. Computed tomography versus ultrasound of the adrenal gland: a prospective study. Radiology 1982 143 121–128.
124. Suzuki Y, Sasagawa I, Suzuki H, Izumi T, Kaneko H & Nakada T. The role of ultrasonography in the detection of adrenal masses: comparison with computed tomography and magnetic resonance
imaging. International Urology and Nephrology 2001 32 303–306.
125. Fontana D, Porpiglia F, Destefanis P, Fiori C, Alı A, Terzolo M, Osella G & Angeli A. What is the role of ultrasonography in the follow up of adrenal incidentalomas? Urology 1999 54 612–616
126. Rubello D, Bui C, Casara D, Gross MD, Fig LM & Shapiro B. Functional scintigraphy of the adrenal gland. European Journal of Endocrinology 2002 147 13–28.
127.  Falke TH & Sandler MP. Classification of silent adrenal masses: time to get practical. Journal of Nuclear Medicine 1994 35 1152–1154.
128.  Gross MD, Shapiro B, Bouffard AJ, Glazer GM, Francis IR, Wilton GP, Khafagi F & Sonda LP. Distinguishing benign from malignant euadrenal masses. Annals of Internal Medicine 1998 109 613–618.
129. Gross MD, Shapiro B, Francis IR, Glazer GM, Bree RL, Arcomano MA, Schteingart DE, Mc Leod MK, Sanfield JA & Thompson NW. Scintigrafic evaluation of clinically silent adrenal masses. Journal of Nuclear Medicine 1994 35 1145–1152.
130. Rossi GP, Sacchetto A, Chiesura-Corona M, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic
resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001;86:1083–1090.
131. Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. RadioGraphics 2005;25(suppl 1):S143–S158.
132. Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, Halpern EF, Mueller PR, Hahn PF & Boland GW. Distinguishing benign from malignant adrenal masses: multidetector row CT protocol with 10-minute delay. Radiology 2006 238 578–585.
133. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, Reddy S, Gill IS, Siperstein A & Bravo EL. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic
experience. Journal of Clinical Endocrinology and Metabolism 2005 90 871–877.
134. Lee MJ, Hahn PF, Papanicolaou N, Egglin TK, Saini S, Mueller PR & Simeone JF. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 1991 179 415–418.
135. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR & Londy F. CT time–attenuation washout curves of adrenal adenomas and nonadenomas. American Journal of Roentgenology 998 170 747–752.
136. Pena CS, Boland GW, Hahn PF, Lee MJ & Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast enhanced CT. Radiology 2000 217 798–802.
137. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR & Raghupathi KI. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002 222 629–633.
138. Szolar DH & Kammerhuber FH. Adrenal adenomas and nonadenomas: assessment of washout at delayed contrastenhanced CT. Radiology 1998 207 369–375.
139. Marlies J.E. Kempers, Jacques W.M. Lenders, Lieke van Outheusden, Gert Jan van der Wilt, Leo J. Schultze Kool, Ad R.M.M. Hermus, Jaap Deinum. Systematic Review: Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism. Ann Intern Med. 2009;151:329-337.
140. Dunnick NR, Londy F, Shapiro B, Gross MD & Thompson NW. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995 197 411–418.
141. Outwater EK, Siegelman ES, Radecki PD, Piccoli CW & Mitchell DG. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. American Journal of Roentgenology 1995 165 579–583.
142. Bilbey JH, McLoughlin RF, Kurkjian PS, Wilkins GE, Chan NH, Schmidt N & Singer J. MR imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other tumors. American Journal of Roentgenology 1995 164 637–642.
143. McNicholas MM, Lee MJ, Mayo-SmithWW, Hahn PF, Boland GW & Mueller PR. An imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. American Journal ofRoentgenology 1995 165 1453–1459.
144. Heinz-Peer G, Ho¨nigschnabl S, Schneider B, Niederle B, Kaserer K & Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. American Journal of Roentgenology 1999 173 15–22.
145. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM & Mueller PR. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-
deoxy-D-glucose. Radiology 1995 194 131–134.
146. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE & Goodman PC. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose
positron emission tomography. American Journal of Roentgenology 1997, 168 1357–1360.
147. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, Ziviello M & Salvatore M. Imaging of adrenal tumors using FDG-PET: comparison of benign and malignant lesions.
American Journal of Roentgenology 1999 173 25–29.
148. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S & Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. Journal of Nuclear Medicine 2001 42 1795–1799.
149. Tenenbaum F, Groussin L, Foehrenbach H, Tissier F, Gouya H, Bertherat J, Dousset B, Legmann P, Richard B & Bertagna X. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive patients European
Journal of Endocrinology 2004 150 789–792.
150. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR & Boland GW. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy – initial experience. Radiology 2006 238 970–977.
151. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Langsjo¨ J, Salmi J, Valimaki M, Nagren K & Nuutila P. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)FFDG. Journal of Nuclear Medicine 2004 45 972–979.
152. Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A & Hellman P. [11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. Journal of Clinical Endocrinology and Metabolism 2006 91 1410–1414.
153. Timothy J. Burton, Isla S. Mackenzie, Kottekkattu Balan, Brendan Koo, Nick Bird, Dmitri V. Soloviev, Elena A. B. Azizan, Franklin Aigbirhio, Mark Gurnell, Morris J. Brown. Evaluation of the Sensitivity and Specificity of 11C-Metomidate Positron Emission Tomography (PET)-CT for Lateralizing Aldosterone Secretion by Conn’s Adenomas, J Clin Endocrinol Metab 97: 0000–0000, 2012
154. Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011 Dec 1;18(6):R253-76.
155. Majumdar S, Friedrich CA, Koch CA, Megason GC, Fraktin JD, Moll GW. Compound heterozyous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma. Pediatr Blood Cancer 2010;54:473-475.
156. de Wally P, Oragano L, Rade F, Beaulieu A, Arnault V, Levillain P, Kraimps JL. Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg 2012;
157. Eisenhofer G, Lenders JWM, Timmers H, Mannelli M, Grebe SK, Hofbauer LC, Bornstein SR, Tiebel O, Adams K, Braslavsky G, Linehan WM, Pacak K. Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. Clinical Chemistry 2011;57:3 411–420.
158. Plouin PF, Degoulet P, Tugaye A, Ducrocq MB & Menard J. [Screening for
phaeochromocytoma : in which hypertensive patients? A semiological study of 2585
patients, including 11 with phaeochromocytoma (author's transl)]. Nouv Presse Med.1981;10 869-872.
159. Lenders, J.W., et al., Phaeochromocytoma. Lancet 2005;366(9486): p. 665-75.
160. Motta-Ramirez GA, Remer EM, Herts BR, Gill IS, Hamrahian AH. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185(3):684-8.
161. Kushnir MM, Urry FM, Frank EL, Roberts WL, Shushan B. Analysis of catecholamines in urine by positive-lon electrospray tandem mass spectrometry. Clinical Chemistry 2002;48:323-331.
162. Peaston RT, Graham KS, Chambers E, van der Molen JC, Ball S. Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. Clin Chim Acta. 2010;411(7-8):546-52.
163. Taylor RL, Singh RJ. Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clinical Chemistry 2002;48:533-539.
164. Modified after: Nicola MN, Kathryn SK, Karel P. Drugs and Pheochromocytoma — Don’t Be Fooled by Every Elevated Metanephrine. N Engl J Med 2011;364 (23):2268-2270
165. Eisenhofer G, Keiser H, Priberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998;83:533-522.
166. Lenders JWM, Pacak K, Eisenhofer G. New advances in biochemical diagnosis of pheochromocytoma. NY Acad Sci 2002; 970:29-40.
167. Shao Y, Chen R, Shen ZJ, Teng Y, Huang P, Rui WB, Xie X, Zhou WL. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary ? J Hypertens 2011;29(12):2429-2432
168. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287:1427-1434.
169. Eisenhofer G, Huysmans F, Pacak K, Walther MM, Sweep FC, Lenders JW. Plasma metanephrines in renal failure. Kidney Int. 2005;67(2):668-77.
170. Whitman HH 3rd, Fishman EK, Oberg K, et al., Catecholamine secreting metastatic carcinoid as differential diagnosis in pheochromocytoma: clinical, laboratory, and imaging clues in the search for the lurking neuroendocrine tumor (NET),Ann N Y Acad Sci, 2006;1073:59–78.
171. Miehle K, Kratzsch J, Lenders JW, Kluge R, Paschke R, Koch CA. Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines. J Endocrinol Invest. 2005;28(11):1040.
172. Lenders JW, Pacak K, Huynh TT, Sharabi Y, Mannelli M, Bratslavsky G, Goldstein DS, Bornstein SR, Eisenhofer G. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab. 2010;(1):238-45.
173. Sebel E, Hull R, Kleerekoper M, Stokes G. Responses to glucagon in hypertensive patients with and without a pheochromocytoma. Am. J Med Sci 1974; 267:337-343.
174. Sarathi V, Lila AR, Bandgar TR, Menon PS, Shah NS. Pheochromocytoma and pregnancy: a rare but dangerous combination. Endocr Pract. 2010; Mar-Apr;16(2):300-9.
175. Anna M Sawka, Ally PH Prebtani, Lehana Thabane, Amiram Gafni,Mitchell Levine, William F Young Jr. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma.BMC Endocrine Disorders 2004, 4:2
176. Singer J, Koch CA, Kassahun W, Lamesch P, Eisenhofer G, Kluge R, Lincke T, Seiwerts M, Borte G, Schierle K, Paschke R. A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. Nat Rev Endocrinol 2011;7(12):749-55.
177. Bravo E, Tarazi R, Fouad F, Vidt D, Gilford R. Clonidine suppression test. A useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305:623-626.
178. Sjoberg RJ, Simcic KJ, Kid GC. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992; 152:1193-1197.
179. Zuetenhorst JM, Taal BG, Metastatic carcinoid tumors: a clinical review, Oncologist 2005;10:123–31.
180. Kunwar S S Bhatia, Mohamed M Ismail, Anju Sahdev, Andrea G Rockall, Kieran Hogarth, … Ana Canizales, Norbert Avril, John P Monson, Ashley B Grossman, Rodney H Reznek. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.Clinical Endocrinology 2008;181-188.
181. Tim Scholz, Graeme Eisenhofer, Karel Pacak, Henning Dralle, and Hendrik Lehnert. Current Treatment of Malignant Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism 2007; 92(4):1217–1225.
182. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513–521.
183. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC.Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989; 30:481–489.
184. Carnaille B, Nocaudie M, Pattou F, et al., Scintiscans and carcinoid tumors. Surgery, 1994;116:1118–21.
185. Hoefnagel CA, Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours, Eur J Nucl Med 1994;21:561–81.
186. Bomanji J, Mather S, Moyes J, et al., A scintigraphic comparison of iodine-123 metaiodobenzylguanidine and an iodine-labeled somatostatin analog (Tyr-3-octreotide) in metastatic carcinoid tumors, J Nucl Med 1992;33:1121–4.
187. Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, Hartmann O, Hoefnagel CA, Jamadar DA, Kloos R, Lizotte P, Lumbroso J, Rufini V, Shulkin BL, Sisson JC, Thein A, Troncone L. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 1997; 38:1352–1357
188. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;1140–1146.
189. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49(8):1232-7.
190. Henri J. L. M. Timmers, Clara C. Chen, Jorge A. Carrasquillo, Millie Whatley, Alexander Ling, Bastiaan Havekes, Graeme Eisenhofer, Lucia Martiniova, Karen T. Adams, and Karel Pacak, Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro- Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab, December 2009,94(12):4757–4767.
191. Gonca Kara Gedik & Cornelis A. Hoefnagel & Evert Bais & Renato A. Valdés Olmos. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma  Eur J Nucl Med Mol Imaging 2008; 35:725–733.
192. Flavio F, Roelf V, Dik JK, Marion de Jong, Eric PK. Peptide receptor radionuclide therapy. Best Practice & Research Clinical Endocrinology & Metabolism 2007;111–129
193. Pettinato C, Sarnelli A, Di Donna M, et al., 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors, Eur J Nucl Med Mol Imaging, 2008;35:72–9.
194. M Terzolo, A Stigliano, I Chiodini, P Loli, L Furlani, G Arnaldi, G Reimondo, A Pia, V Toscano, M Zini, G Borretta, E Papini, P Garofalo, B Allolio, B Dupas, F Mantero, A Tabarin. AME Position Statement on adrenal incidentaloma. European Journal of Endocrinology 2011;164 851–870.
195. Shackleton CH: Profiling steroid hormones and urinary steroids. J Chromatogr 1986; 379:91-156.
196. Paolo Ferrari, Mario G. Bianchetti, Diagnostic investigations in inherited endocrine disorders of sodium regulations from Ranke MB, Mullis PE (eds.): Diagnostic of endocrine function in children and adolescents, 4th edition, Basel, Karger, 2011, pp 210-234.
197. Ferrari P,Bonny O: Forms of mineralocorticoid hypertension. Vitam Horm 2003;66:113-156.
198. Morineau G, Sulmont V, Salomon R, Fiquet-Kempf B, Jeunemaitre X, Nicod J, Ferrari P. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol 2006;17:3176-3184.
199. Ulick, S., L.S. Levine, P. Gunczler, et al. J. Clin. Endocrinol. Metab 1979;49: 757–764.
200. Vehaskari VM. Heritable forms of hypertension. Pediatr Nephrol.2009;24(10):1929-37.
201. Hiltunen TP, Hannila-Handelberg T, Petajaniemi N et al. Liddle's syndrome associated with a point mutation in the extracellular domain of the epithelial sodium channel gamma subunit. J Hypertens 2002; 20(12):2383-2390.
202. Abriel, H, Loffing, J., Rebhun, J. F., Pratt, J. H., Schild, L., Horisberger, J.-D., Rotin, D., Staub, O. Defective regulation of the epithelial Na(+) channel by Nedd4 in Liddle's syndrome. J. Clin. Invest 1993; 103: 667-673
203. Yang CL, Angell J, Mitchell R, Ellison DH: WNK kinases regulate tiazide-sensitive NaCl cotransport. J Clin Invest 2003;111:1039-1045